An interventional study of Xtrodes home PSG system in Parkinson Disease, GBA Gene Mutation and Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation, sponsored by Tel-Aviv Sourasky Medical Center. Recruiting at 1 site in Israel. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-10.
Sponsored by Tel-Aviv Sourasky Medical Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · Tel-Aviv Sourasky Medical Center.
Among the 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2020, is one of 13 with no phase, and was the 20th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →4 of the 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center are open now, in 1 country. Recruiting first, the newest first:
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 40–85
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 18+
Tel-Aviv Sourasky Medical Center
Ages 25–90
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2020.
This study's planned enrollment of 240 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 50 across the 14 interventional studies, 60 across the 9 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tel-Aviv Sourasky Medical Center is the lead sponsor of 555 studies on the registry; 52 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Parkinson Disease by Tel-Aviv Sourasky Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye Movement (REM) sleep behavior disorder and sleep-disordered breathing) have been associated with an increased risk of neurodegeneration and are an independent risk for cognitive decline and dementia in PD.
Although much is currently unknown about sleep changes in PD, sleep-related symptoms are increasingly recognized as a major contributor to disease burden and reduced quality of life among people with PD. The "gold standard" evaluation of nocturnal sleep is polysomnographic monitoring (PSG).
This study proposes to use novel wireless skin electrodes and wearable sensors to provide a "home PSG test" incorporating several physiologic recordings, over multiple nights in the person's home, enabling the objective evaluation of night-to-night fluctuations.
Background Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye Movement (REM) sleep behaviour disorder and sleep-disordered breathing) have been associated with an increased risk of neurodegeneration and are an independent risk for cognitive decline and dementia in PD. The etiology of impaired sleep and alertness in PD is multifactorial and may be due to the interactions between internal and external factors such as primary sleep disorders, primary neurodegeneration, medication side effects, environmental conditions and genetic factors (either associated with sleep or associated with disease phenotype). Each can contribute to sleep disturbances alone or as modifiers, resulting in variability of presentation and symptoms, affecting both the diagnosis, and the treatment of these disorders. Although much is currently unknown about sleep changes in PD, sleep-related symptoms are increasingly recognized as a major contributor to disease burden and reduced quality of life among people with PD.
The "gold standard" evaluation of nocturnal sleep is polysomnographic monitoring (PSG). PSG consists of measuring neural function, eye movements, muscle activity, respiratory status and electrocardiography activity while the person sleeps over-night in a laboratory setting. This assessment allows for quantification of the different sleep stages during non-REM and REM, evaluation of their distribution over the course of the night, and the identification of impairments in each of these stages. However, PSG is time, cost and labor-intensive, may not reflect the typical behavior of the person due to the unfamiliar environment and irregular sleeping conditions, and more importantly, only provides information on one night of sleep.
In recent years, there is heightened interest in home-based sleep monitoring via wearable sensors to address these shortcomings. Body-fixed electrophysiological sensors can objectively quantify sleep quality, generating a detailed map of the person's sleeping pattern and nocturnal movements. They are relatively inexpensive enabling wide-spread use.
This study proposes to use novel wireless skin electrodes and wearable sensors to provide a "home PSG test" incorporating several physiologic recordings, over multiple nights in the person's home, enabling the objective evaluation of night-to-night fluctuations. By applying these novel tools to the study of people with PD as well as controls and subjects at risk for developing PD, the results of this study will open the door for using a new method for assessment of prodromal signs and disease progression.
Study objective
Main objective is to use the combined wearable system described above to evaluate sleep disturbances across a wide spectrum of PD disease severity: from the prodromal phase with individuals at risk to mild and advanced PD:
Subjects will be recruited and evaluated from the Laboratory for Early Markers of Neurodegeneration (LEMON) at the Neurological Institute at the Tel Aviv Medical Centre (TLVMC). All subjects will provide informed written consent as approved by each TLVMC's ethical committee and in accordance with the Helsinki agreement prior to participation.The 'Genetics in Parkinson's Study' registry will be used for initial recruitment of participants. This is a registry of participants (patients and family members who have undergone genetic testing in our lab previously and have agreed to allow contact for future studies (under Helsinki agreement of 05-069 and 07-0381). PD patients will be approached by their physician to provide consent to participate in the sleep study. Asymptomatic participants will be recruited from the registry or from public advertisements and word to mouth approach. Those willing to participate will be invited to LEMON for an assessment meeting. Subjects will be provided with a detailed explanation of the study protocol before being asked to sign the consent form.
Procedures:
After signing an informed written consent, participants will be asked about their current and medical history, sleep habits, dietary, alcohol and caffeine consumption and any medication they are receiving. Subjects will then undergo a through neurological assessment and blood pressure supine and standing, pulse rates, weight, height will be obtained.
A blood sample (15 cc) will be drawn to test the association to metabolic, hormonal and inflammatory mediators known to affect sleep (specifically: iron stores, thyroid function, and hemoglobin). Subjects will also undergo several performance based assessments and questionnaires on sleep and behavior.
All subjects will then be scheduled for a sleep polysomnography (PSG). Subjects will be invited to the sleep lab at TLVMC and asked to arrive at 9 pm and will be instructed on all procedures. Several body functions will be recorded during the PSG including brain activity, eye movement, oxygen and carbon dioxide blood levels, heart rate and rhythm, breathing rate and rhythm, the flow of air through the mouth and nose, body muscle movements, and chest and belly movement. The standard PSG will be fitted first and then the Xtrode system will be placed on the subject's face and the Axivity sensor will be placed on the subjects back (L4-5) using medical tape. This process should take approximately 45 minutes. After the systems are turned on, the subjects will be left in the quite room for a night sleep. The session will be video-taped to enable a comparison of movement with the wearable systems. The PSG and Xtrodes systems will be removed no later than 8 am the next morning.
Subjects will then be instructed on how to use the sleep "tattoo" at home. The system provided will include the controller, seven skin adhesives and a smartphone app, which will be used to obtain the data collected. Data is automatically transferred from the skin tattoo directly to the smartphone via a Bluetooth connection. The Axivity device which was placed on the lower back of the subjects will remain in place for the remaining 7 days. The device is waterproof thus there is no need for the subjects to don or doff the device until the end of the collection period. After the study, the systems will be returned to the medical centers for data transfer and analysis via carrier.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Wireless wearable system incorporates EEG, electrooculography (EOG) and EMG recordings over multiple nights in the home environment. The electrodes are printed on a thin sticker. These printed electrodes are marked by their conformity with the skin, light weight, ease of placement on the skin, and user comfort. The sleep-specific electrode array includes two surface EMG (electrodes 1 and 2), two EOG (electrodes 3 and 4) and four forehead EEG electrodes (electrodes 5-8) .
Device: Xtrodes home PSG system
Wireless, convenient and relies on actual recording of EMG, EOG and EEG in a home setting
Also known as: Home PSG system
Changes in sleep architecture
Frequency of RBD and severity of sleep interruptions
Time frame: From placing the system to disassembling, up to 1 week
MDS-UPDRS
MDS-UPDRS part III will be used to assess the relationship between sleep disorders and motor disability
Time frame: Immediate after disassembling the system (day 7)
REM Sleep Behavior Disorder Screening Questionnaire
Patient self-rating instrument assessing the subject's sleep behavior with short questions that have to be answered by either "yes" or "no".
Time frame: Immediate after disassembling the system (day 7)
The Non-Motor Scale
The Non-Motor Scale validated and commonly used 30-point questionnaire recognizes the non-motor difficulties often occur in PD. Areas covered include sleep, constipation, vision, smell, sexual problems and memory.
Time frame: Immediate after disassembling the system (day 7)
Geriatric Depression Scale
The Geriatric Depression Scale is a self report assessment used to identify depression in the elderly. The questionnaire consists of 15 yes/no questions; one point is assigned to each answer. Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.
Time frame: Immediate after disassembling the system (day 7)
Started Jun 2020 (actual). Primary completion is estimated for Dec 2023, 42 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 42 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tel-Aviv Sourasky Medical Center →